Helus Pharma Appoints Former Pfizer CMO to Chair Scientific Advisory Committee, Bolstering Phase 3 Program
Helus Pharma named Dr. Freda Lewis-Hall, ex-Pfizer Executive VP and Chief Medical Officer who led global operations in 125 countries, to its board and as Scientific Advisory chair. She will oversee clinical strategy, regulatory engagement and rigor across Helus’s pipeline, including HLP003 in Phase 3 with FDA Breakthrough Therapy Designation.
1. Appointment Details
Helus Pharma has appointed Dr. Freda Lewis-Hall to its board of directors and named her Chair of the Scientific Advisory Committee. In this dual role, she will guide corporate governance and chair scientific discussions, focusing on clinical development strategy, regulatory pathways and translational rigor.
2. Professional Background
Dr. Lewis-Hall brings over 40 years of experience in clinical care and biopharmaceutical leadership, having served on Pfizer’s Executive Leadership Team as Executive VP and Chief Medical Officer overseeing a global medical organization in more than 125 countries. She also led patient engagement and inclusion initiatives as Chief Patient Officer.
3. Pipeline Oversight
In her new position, Dr. Lewis-Hall will advise on Helus’s NSA portfolio, including HLP003 in Phase 3 with FDA Breakthrough Therapy Designation for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder. She will support trial design, regulatory submissions and translational rigor.
4. Strategic Implications
Helus aims to leverage her regulatory and commercialization expertise to accelerate development timelines and strengthen investor confidence. Her track record in guiding the $3.4 billion SpringWorks spinout and advancing global commercial strategies may enhance Helus’s market positioning and valuation outlook.